share_log

Inhibikase Therapeutics To Present Data From Phase 1/1b Study Of IkT-148009 At The Movement Disorders Society Congress

Inhibikase Therapeutics To Present Data From Phase 1/1b Study Of IkT-148009 At The Movement Disorders Society Congress

Inhibikase治疗公司将在运动障碍学会大会上公布IKT-148009的1/1b期研究数据
Benzinga Real-time News ·  2022/09/15 08:07

IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients

在老年健康志愿者和帕金森病患者中,IKT-148009耐受性良好,全身暴露高,并持续渗透到中枢神经系统(CNS)

No clinically significant adverse events observed

未观察到有临床意义的不良反应

Actively enrolling Phase 2a '201' clinical trial of IkT-148009 in patients with untreated Parkinson's disease

在初治帕金森病患者中积极纳入IKT-148009的2a‘201’期临床试验

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发